8 assets in Myelodysplastic Syndrome With Single Lineage Dysplasia

Therapeutic assets addressing Myelodysplastic Syndrome With Single Lineage Dysplasia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fludarabine Myelodysplastic Syndrome With Single Lineage Dysplasia	Fred Hutchinson Cancer Center	P3	BB (71)
Cyclophosphamide Myelodysplastic Syndrome With Single Lineage Dysplasia	Fred Hutchinson Cancer Center	P3	BB (69)
Busulfanum Myelodysplastic Syndrome With Single Lineage Dysplasia	Fred Hutchinson Cancer Center	P3	BB (66)
Tacrolimus Myelodysplastic Syndrome With Single Lineage Dysplasia	Masonic Cancer Center, University of Minnesota	P2	BB (64)
Vorinostat Myelodysplastic Syndrome With Single Lineage Dysplasia	National Cancer Institute (NCI)	P2	B (58)
Thiotepa Myelodysplastic Syndrome With Single Lineage Dysplasia	Fred Hutchinson Cancer Center	P2	B (57)
Azacitidine Myelodysplastic Syndrome With Single Lineage Dysplasia	National Cancer Institute (NCI)	P1/2	CCC (48)
Dilanubicel Myelodysplastic Syndrome With Single Lineage Dysplasia	Fred Hutchinson Cancer Center	P2	CCC (48)